BN.com Gift Guide

Alzheimer Disease: From Molecular Biology to Theraphy

Paperback (Softcover reprint of the original 1st ed. 1997)
$192.72
BN.com price
(Save 15%)$229.00 List Price
Other sellers (Paperback)
  • All (4) from $168.78   
  • New (3) from $168.78   
  • Used (1) from $264.18   
Sending request ...

Editorial Reviews

David O. Staats
This book presents an international review of topics concerning Alzheimer's disease. Its purpose is to provide reviews of current advances in Alzheimer's disease research. The primary audience for this book is those interested in current research in Alzheimer's disease. This book features a variety of areas from molecular biology, approaches to pharmacologic treatment, assessment, clinical approach to diagnosis and management, and ethical concerns. This book represents a truly international perspective. The very short chapters are concise summaries of the approaches to Alzheimer's disease in many different areas. Some represent a synthesis of ideas; others summarize current research. The book appeals mainly to specialists working in the area of Alzheimer's disease; it is clearly not useful as a textbook.
Doody's Review Service
Reviewer: David O. Staats, MD (University of Oklahoma Health Sciences Center)
Description: This book presents an international review of topics concerning Alzheimer's disease.
Purpose: Its purpose is to provide reviews of current advances in Alzheimer's disease research.
Audience: The primary audience for this book is those interested in current research in Alzheimer's disease.
Features: This book features a variety of areas from molecular biology, approaches to pharmacologic treatment, assessment, clinical approach to diagnosis and management, and ethical concerns.
Assessment: This book represents a truly international perspective. The very short chapters are concise summaries of the approaches to Alzheimer's disease in many different areas. Some represent a synthesis of ideas; others summarize current research. The book appeals mainly to specialists working in the area of Alzheimer's disease; it is clearly not useful as a textbook.

2 Stars from Doody
Read More Show Less

Product Details

  • ISBN-13: 9781461286608
  • Publisher: Birkhauser Verlag
  • Publication date: 7/31/2012
  • Series: Advances in Alzheimer Disease Therapy Series
  • Edition description: Softcover reprint of the original 1st ed. 1997
  • Edition number: 1
  • Pages: 614
  • Product dimensions: 6.14 (w) x 9.21 (h) x 1.27 (d)

Table of Contents

Criteria for the Clinical Diagnosis of Alzheimer's Disease: Transcultural Aspects 3
Clinical And Neuropathological Findings from Cerad 7
Differentiating Alzheimer Disease and Vascular Dementia: Reframing the Question 13
Basis of Structural Alzheimer Disease and Some Pathogenic Concepts 19
Regional Distribution of Neuropathological Changes in Alzheimer's Disease 25
Alzheimer Neurofibrillary Degeneration: A Feasible and Key Target for Therapeutics 31
Diabetes and Dementia: A Retrospective Neuropathologic Study of Old Diabetics Compared to Non-Diabetic Controls 37
Isoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer's Disease 47
Apolipoprotein E4 and Cholinergic Activity in Alzheimer's Disease 55
A New Focus on Cytoskeletal Therapy in Alzheimer's Disease 61
Novel Cathepsin D Inhibitors Prevent the [beta]-Secretase-Derived Intracellular Formation of a 12 kDA Potentially Amyloidogenic Product in Human Cells 67
Cellular and Test Tube Models of Amyloid-[beta] Formation 75
Effects of [beta]-Amyloid (1-40) Peptide Injection in the Nucleus Basalis 81
[Beta]-Amyloid Precursor Protein - Role in Cognitive Brain Function? 87
Peptides Inhibitor of Amyloidogenesis in Alzheimer's Disease 91
Apoptosis and Alzheimer's Disease: A Self-Assembly and the Initiation of Apoptosis by Plasma Membrane Receptor Cross-Linking 99
NMDA Receptor Dysfunction in Alzheimer's Disease 107
Role of Neuron-Glia Interactions in Brain Energy Metabolism: Implications for Neurodegenerative Disorders 113
Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer's Disease 119
Cortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy 125
APP Knockout and APP Over-Expression in Transgenic Mice 133
Alpha2c-Adrenoceptor Overexpressing Mice as a Model to Study Cognitive Functions of Alpha2-Adrenoceptors 137
[Beta]-APP-751 Transgenic Mice: Deficits In Learning And Memory 145
Central and Peripheral Consequences of Cholinergic Imbalance in Alzheimer's Disease 153
The Anatomy of Monoaminergic-Cholinergic Interactions in the Primate Basal Forebrain 159
Pharmacological Induction of Cholinergic Hypofunction as a Tool for Evaluating Cholinergic Therapies 165
Rational Design of New Acetylcholinesterase Inhibitors 171
Advances in Understanding Cholinergic Brain Neurons: Implications in the Use of Citicoline (CDP Choline) to Treat Stroke 179
Cholinesterase Inhibitors Do More than Inhibit Cholinesterase 187
Long-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality 205
Cholinesterase Inhibitors: An Overview of Their Mechanisms of Action 211
Preclinical Pharmacology of Metrifonate: A Promise of Alzheimer Therapy 217
Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer's Disease 223
Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and [beta]-APP Processing 231
An Overview of the Development of SDZ ENA 713: A Brain Selective Cholinesterase Inhibitor 239
Preclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor 245
P11467: An Orally-Active Acetylcholinesterase Inhibitor and [alpha][subscript 2]-Adrenoceptor Antagonist for Alzheimer's Disease 251
Cholinesterase Inhibitors as Therapy in Alzheimer's Disease: Benefit to Risk Considerations in Clinical Application 257
Molecular Histochemistry of Nicotinic Receptors in Human Brain 269
The Nicotinic Cholinergic System and [beta]-Amyloidosis 275
RJR-2403: A CNS-Selective Nicotinic Agonist with Therapeutic Potential 281
ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action 287
Biochemistry, Pharmacodynamics and Pharmacokinetics of CI-1002: A Combined Anticholinesterase and Muscarinic Antagonist 293
Muscarinic Partial Agonists in the Symptomatic Treatment of Alzheimer's Disease 299
Safety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer's Disease 305
Pharmacological Characterization of PD151832: An M1 Muscarinic Receptor Agonist 311
Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer's Disease 317
Free Radical Scavengers Block the Actions of [beta]-Amyloid on Neurons in Tissue Culture 323
Therapeutic Strategies in Alzheimer's Disease 329
New Synthetic Bioantioxidants: Acetylcholinesterase (AChE) 337
Rationale to Treat Alzheimer's Disease with Selegiline - Can We Prevent the Progression of the Disease? 343
Inflammatory Processes: Anti-Inflammatory Therapy 349
Propentofylline: Preclinical Data 355
Propentofylline (HWA 285): A Subgroup Analysis of Phase III Clinical Studies in Alzheimer's Disease And Vascular Dementia 361
Anapsos: New Therapeutic Strategies for Neurodegeneration and Brain Aging with Neuroimmunotrophic Factors 367
Clinical Trials to Prevent Alzheimer's Disease in a Population At-Risk 375
Effects on Decline or Deterioration 381
The Bridging Study: Optimizing the Dose for PhaseII/III 387
Assessment of Therapeutic Strategies for Slowing Progression of Alzheimer's Disease 393
Potential for Progress in the Therapeutics of Alzheimer's Disease: Unanswered Questions 399
The A
Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)